FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

starstarstarstarstar

FDA Drug Safety Podcasts

RSS Feed URL

Claim this podcast

Remove this podcast

Play Latest Episode:

Title: FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma

February 28th, 2020

FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib… Go to Episode

FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer

February 28th, 2020

FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metastatic… Go to Episode

FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur

February 28th, 2020

FDA D.I.S.C.O.: Intro by Dr. Richard Pazdur In our inaugural podcast, Dr. Richard Pazdur, director of the FDA Oncology Center of Excellence, talks with… Go to Episode

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

February 28th, 2020

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer FDA medical oncologists discuss the agency’s December 2016 accelerated approval of rucaparib for treatment… Go to Episode